

# UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No. 20721YCA  
First Inventor or Application Identifier Bilodeau et al.  
Title TYROSINE KINASE INHIBITORS  
Express Mail Label No. EV321986454US

## APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

ADDRESS TO: Mail Stop Patent Application  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

1. ☒ Fee Transmittal Form  
(Submit an original, and a duplicate for fee processing)
2. ☒ Specification [ Total Pages 169 ]
3. ☐ Drawing(s) (35 USC 113) [ Total Sheets ]
4. Oath or Declaration
  - a. ☐ Newly executed (original or copy)
  - b. ☒ Copy from a prior application (37 CFR 1.63(d))  
(for continuation/divisional with Box 14 completed)
    - i. ☐ DELETION OF INVENTOR(S)  
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33 (b).
5. ☐ Application Data Sheet. See 37 CFR 1.76
6. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
  - a. ☐ Computer Readable Form (CRF)
  - b. ☐ Specification Sequence Listing on:
    - i. ☐ CD-ROM or CD-R (2 copies); or
    - ii. ☐ paper
  - c. ☐ Statements verifying identity of above copies

## ACCOMPANYING APPLICATION PARTS

7. ☐ Assignment papers (cover sheet & document(s))
8. ☐ 37 CFR 3.73(b) Statement (when there is an assignee) ☐ Power of Attorney
9. ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
10. ☒ Preliminary Amendment
11. ☒ Return Receipt Postcard (MPEP 503)  
(Should be specifically itemized)
12. ☐ Certified Copy of Priority Document(s)  
(if foreign priority is claimed)
13. ☒ Other: Associate Power of Attorney

14. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

☒ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No. 09 / 990,473

Prior application information: Examiner D. R. Rao

Group/Art Unit: 1624

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference.

## 15. CORRESPONDENCE ADDRESS

☒ Customer Number

Customer No. 000210

NAME	Matthew A. Leff						
ADDRESS	Merck & Co., Inc., P. O. Box 2000 - Patent Dept., RY60-30						
CITY	Rahway	STATE	NJ	ZIP CODE	07065-0907		
COUNTRY	USA	TELEPHONE	732-594-1404	FAX	732-594-4720		

Name	Matthew A. Leff	Registration No. (Attorney/Agent)	50,149
Signature		Date	10/2/2003

## EXPRESS MAIL CERTIFICATE

DATE OF DEPOSIT October 2, 2003

EXPRESS MAIL NO. EV321986454US

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE" ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

MAILED BY Ron Schep DATE October 2, 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents,  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Prior Application:

Examiner	D. R. Rao
Art Unit	1624

Sir: This is a request for filing a ☒ Continuation ☐ Divisional

application, under 37 C.F.R. 1.53(b), of pending application Serial No. 09/990,473 filed on

11/21/01 (DATE) of Mark T. Bilodeau et al. (INVENTOR)

for TYROSINE KINASE INHIBITORS (TITLE OF INVENTION)

1. The enclosed comprises a copy of prior application Serial No. 09/990,473, as filed on 11/21/01. The entire disclosure of this prior application is hereby incorporated by reference.

2. The filing fee is calculated below:

CLAIMS AS FILED IN THE PRIOR APPLICATION, LESS ANY CLAIMS CANCELED BY AMENDMENT BELOW

FOR	NUMBER FILED	NUMBER EXTRA	RATE	FEE
Total Claims	35 - 20	15 x	\$18	\$270
Independent Claims	6 - 3	3 x	\$86	\$258
*Multiple Dependent Claims			\$290	
Basic Fee (minimum amount required)				\$770
				\$1,298
				Total Fee

\* Add this fee if application contains any multiple dependent claims, regardless of number.

3. The Commissioner is hereby authorized to charge any fees which may be required or to credit any overpayment to Account No. 13-2755.

4. ☐ Amend the specification by inserting before the first line the sentence:  
-- This is a ☐ continuation, ☐ division of application Serial No. \_\_\_\_\_, filed \_\_\_\_\_.
5. ☐ Cancel in this application original claims: \_\_\_\_\_.
6. ☒ Preliminary amendment enclosed.
7. ☐ Information Disclosure Statement/PTO-1449 enclosed.
- 8a. ☐ Transfer the drawings from the prior application to this application and abandon said prior application as of the filing date accorded this application. A duplicate copy of this sheet is enclosed for filing in the prior application file.
- 8b. ☐ New formal drawings are enclosed.
- 9a. ☐ Priority of application Serial No. \_\_\_\_\_, filed \_\_\_\_\_, in \_\_\_\_\_ (COUNTRY) is claimed under 35 U.S.C. 119.
- 9b. ☐ The certified copy of the priority application has been filed in prior application Serial No. \_\_\_\_\_, filed \_\_\_\_\_.
10. ☒ The prior application is assigned to Merck & Co., Inc.
11. ☒ The undersigned attorney or agent has:
- a. ☐ Power in the prior application as originally filed.
- b. ☒ Associate power, copy enclosed.

EXPRESS MAIL CERTIFICATE


DATE OF DEPOSIT 10/2/2003

EXPRESS MAIL NO. EV321986454US

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE" ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VIRGINIA 22313-1450.

MAILED BY Kore Schepers DATE 10/2/2003

Respectfully,



By: Matthew A. Left

Agent \_\_\_\_\_ for Applicant(s)

Registration No. 50,149

Telephone: (732) 594-1404

Address: Merck & Co., Inc.  
Patent Department  
P.O. Box 2000 - RY60-30  
Rahway, N.J. 07065-0907

Date: 10/2/2003

Enclosure

IN DUPLICATE